Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease myelodysplastic syndrome
Comorbidity C0002871|anemia
Sentences 32
PubMedID- 25018950 If at all esa responsive, the anemia in patients with myelodysplastic syndrome responds more slowly.
PubMedID- 21381892 Background: current guidelines support the use of erythropoiesis-stimulating agents for the treatment of anemia associated with low-risk myelodysplastic syndromes (mds).
PubMedID- 25485173 Background: erythropoiesis-stimulating agents (esas) are widely used to treat anemia associated with myelodysplastic syndromes (mds) as an off-label indication.
PubMedID- 22550403 Only six cases of leukemia/myelodysplastic syndrome were identified in patients with sickle cell anemia treated with hydroxyurea.
PubMedID- 21226301 An 85-year-old woman, who had been given a diagnosis of myelodysplastic syndrome with refractory anemia 2 years previously and required blood transfusion once a month, was admitted with complaints of fever, general fatigue, and dry cough.
PubMedID- 20569983 We performed an open-labeled single-arm prospective phase ii clinical trial of vitamin k(2) (menatetrenone: vk2) monotherapy and vk2 plus 1alpha-hydroxyvitamin d(3) (alfacalcidol: vd3) combination therapy for myelodysplastic syndromes (mds) with refractory anemia and refractory cytopenia with multilineage dysplasia, having either low or intermediate-1 risks of the ipss.
PubMedID- 24675455 Patients affected by myelodysplastic syndromes (mds) with transfusion-dependent anemia are destined to develop iron overload.
PubMedID- 23523473 Erythropoiesis-stimulating agents (esa) are used commonly to reduce symptomatic anemia in patients with myelodysplastic syndromes (mds).
PubMedID- 26171179 The aim of this the study was to verify that biosimilar epoetin-alpha is similar in terms of efficacy, safety and cost to originator epoetin-alpha for the treatment of refractory anemia in patients with myelodysplastic syndrome.
PubMedID- 20809214 Epo+gcsf combination therapy has proven useful in the treatment of patients with refractory anemia due to myelodysplastic syndrome by a synergistic inhibition of progenitor cell apoptosis, [36] and possibly by enhancement of stem cell mobilization [37].
PubMedID- 25638763 Patients who were not treated exclusively in the hematology and oncology service, hc-ufpr were excluded as were those who had biphenotypic leukemia, fanconi anemia either associated with myelodysplastic syndrome or in isolation, those who were diagnosed before 2003 and those whose medical records were not available.
PubMedID- 22525275 Allelic deletion of the rps14 gene is a key effector of the hypoplastic anemia in patients with myelodysplastic syndrome (mds) and chromosome 5q deletion (del(5q)).
PubMedID- 20367566 Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life.
PubMedID- 20052416 When we examined chk1 expression in this data set, we found it significantly decreased in patients suffering from myelodysplastic syndromes with refractory anemia with blasts [29] (figure 7b).
PubMedID- 25971272 [cold autoimmune hemolytic anemia complicated with relapsed myelodysplastic syndrome after allogeneic hematopoietic cell transplantation].
PubMedID- 23897263 Correlation between dysplastic lineage and type of cytopenia in myelodysplastic syndromes patients with refractory anemia according to the fab classification.
PubMedID- 25563701 Erythropoiesis-stimulating agents (esas) used for chronic anemia management in patients with myelodysplastic syndromes (mds) are commonly injected in a physician office but can be administered safely at home.
PubMedID- 23316859 This drug has been approved by the food and drug administration for transfusion-dependent anemia due to low-risk myelodysplastic syndromes (mds) associated with deletion 5q abnormality with or without additional cytogenetic abnormalities and multiple myeloma in combination with dexamethasone.
PubMedID- 22934211 Our patient has a long-standing history of clonal (5q minus) myelodysplastic syndrome associated with refractory normocytic anemia and small hypolobated megakaryocytes.
PubMedID- 21625998 Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
PubMedID- 22584540 Copper deficiency manifested in all of our patients as either microcytic anemia or pancytopenia with myelodysplastic syndrome.
PubMedID- 21338284 Lenalidomide is approved for use in low/intermediate-1 risk myelodysplastic syndromes associated with transfusion-dependent anemia and a deletion 5q cytogenetic abnormality and, in combination with dexamethasone, in relapsed myeloma.
PubMedID- 25428262 The splicing factor sf3b1 is the most commonly mutated gene in the myelodysplastic syndrome (mds), particularly in patients with refractory anemia with ring sideroblasts (rars).
PubMedID- 24958999 The goal of this study was to explore the plasma proteome of myelodysplastic syndrome (mds) patients with refractory anemia with excess blasts subtype 2 (raeb-2) in comparison to healthy controls.
PubMedID- 24716056 Final diagnosis was high-grade myelodysplastic syndrome consistent with refractory anemia with excess blasts.
PubMedID- 21434945 In many patients with refractory anemia associated with lower risk myelodysplastic syndromes and a 5q chromosome deletion, lenalidomide leads to transfusion independence, considerably improving quality of life.
PubMedID- 25579702 Darbepoetin alfa for anemia with myelodysplastic syndrome.
PubMedID- 26379438 Background: lenalidomide is approved for treating transfusion-dependent anemia due to lower-risk del(5q) myelodysplastic syndromes (mds).
PubMedID- 20037898 The findings were diagnostic of myelodysplastic syndrome with refractory anemia with excess of blasts in accordance with the world health organization criteria modified for pediatric age group.
PubMedID- 24627811 Her past medical history was significant for atrial fibrillation, hypertension, diabetes mellitus, coronary artery disease, cardiomyopathy, hypothyroidism, myelodysplastic syndrome with chronic anemia, cerebrovascular accident, chronic kidney disease, peptic ulcer disease, peripheral vascular disease, and pulmonary hypertension.
PubMedID- 23358617 Darbepoetin (dar), with or without granulocyte colony-stimulating factor (g-csf), has proved effective in treating anemia in patients with lower-risk myelodysplastic syndrome (mds), but its effects on quality of life (qol) and exercise functioning are less well established.
PubMedID- 20485382 Nearly all patients develop aplastic anemia, and nearly half of patients develop myelodysplastic syndrome or acute myeloid leukemia.

Page: 1